2016
Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009–2013
Olmsted G, Farrelly J, Post G, Smith J. Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009–2013. Journal Of Feline Medicine And Surgery 2016, 19: 568-575. PMID: 26951557, PMCID: PMC11128809, DOI: 10.1177/1098612x16638118.Peer-Reviewed Original ResearchConceptsOral squamous cell carcinomaSquamous cell carcinomaToceranib phosphateCell carcinomaTreatment modalitiesFeline oral squamous cell carcinomaMetabolic toxicityNon-steroidal anti-inflammatory drugsCurrent treatment optionsFavorable toxicity profileCommon oral tumorAnti-inflammatory drugsMajority of catsAdditional therapyGastrointestinal toxicityGI toxicityMedian doseSurgical excisionTreatment delayPoor prognosisTreatment optionsOral tumorsDose reductionRadiation therapyToxicity profile
2005
A Phase I Clinical Trial Evaluating Imatinib Mesylate (Gleevec) in Tumor‐Bearing Cats
Lachowicz J, Post G, Brodsky E. A Phase I Clinical Trial Evaluating Imatinib Mesylate (Gleevec) in Tumor‐Bearing Cats. Journal Of Veterinary Internal Medicine 2005, 19: 860-864. PMID: 16355681, DOI: 10.1111/j.1939-1676.2005.tb02778.x.Peer-Reviewed Original ResearchConceptsPhase I clinical trialPO q24hImatinib mesylateClinical trialsSerum biochemistryMinimal gastrointestinal toxicityTumor-bearing catsTumor‐Bearing CatsDiagnosis of fibrosarcomaSquamous cell carcinomaTyrosine kinase inhibitorsMast cell tumorsSigns of toxicityAbdominal ultrasonographyConcurrent chemotherapyGastrointestinal toxicityDose escalationCell carcinomaCell tumorsThoracic radiographsQ24hRadiation therapyMost catsFurther evaluationKinase inhibitors